News 2026.07.07

KRW 150 Trillion National Growth Fund Names K-Bio a Key Pillar… Medical AI Firms Including Portfolio Company VUNO Expected to Benefit

The government-established KRW 150 trillion National Growth Fund has selected bio as a core investment area alongside AI and semiconductors, presenting innovative new drugs, next-generation modalities, and digital healthcare and medical AI as its three investment themes.
With large-scale funding already executed for companies such as LigaChem Biosciences (KRW 500 billion) and SK bioscience (KRW 300 billion in low-interest loans), the industry is highlighting medical AI companies, including SBI Investment portfolio company VUNO as well as Lunit and JLK, as promising beneficiaries.
Industry support, once limited to early-stage R&D, is expanding to the provision of infrastructure for commercial scale-up, and the scope of investment is expected to widen further to CDMOs and suppliers of bio raw materials and equipment.

The full article is available at the link below.